Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2016 3,25 M
EBIT 2016 -23,8 M
Net income 2016 -23,5 M
Debt 2016 4,25 M
Yield 2016 -
Sales 2017 5,85 M
EBIT 2017 -21,8 M
Net income 2017 -21,7 M
Debt 2017 11,0 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 40,0x
EV / Sales2017 23,4x
Capitalization 126 M
More Financials
Company
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases.It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AsiDNA.The company was founded by Gilles Avenard and Dominique Costantini on... 
Sector
Pharmaceuticals
Calendar
10/25Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
07/07 ONXEO COLLABORATES WITH THE ROYAL CO : Onxeo samarbejder med Royal College of Su..
07/05 ONXEO : Receives USPTO Notice of Allowance for Key AsiDNATM Patent, Extending IP..
07/04 ONXEO RECEIVES USPTO NOTICE OF ALLOW : Onxeo modtager “Notice of Allowance..
06/27 ONXEO ADVANCES DEVELOPMENT PLAN FOR : Onxeo offentliggør udviklingsplan for det..
06/27 ONXEO : advances development plan for first-in-class signal interfering DNA comp..
06/03 ONXEO : Announces Development of Beleodaq Oral Formulation Opening New Opportuni..
06/02 ONXEO ANNOUNCES DEVELOPMENT OF BELEO : Onxeo offentliggør udviklingen af en oral..
05/02 PUBLICATION OF 2015 REFERENCE DOCUME : Offentliggørelse af Reference Document fo..
04/28 ONXEO : First Quarter 2016 Financial information and Business Update
04/06 ONXEO : Passing on Onxeo’s Extraordinary and Ordinary General Meeting // D..
More news
Sector news : Pharmaceuticals - NEC
09:06p GlaxoSmithKline to pay $20 million to settle U.S. foreign bribery case
09:00pDJSHIRE : Files 8K - Other Events
07:26aDJNovo Nordisk Announces Job Cuts
09/29DJGLAXOSMITHKLINE : Appoints New Consumer Healthcare Chief
09/29DJNOVO NORDISK A/S : to Cut 1,000 Jobs Amid Growing Competition -- Update
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 9,00 €
Spread / Average Target 197%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Joseph S. Zakrzewski Non-Executive Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Graham K. Dixon Chief Scientific Officer
David Horn Solomon Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOALLIANCE PHARMA SA141
JOHNSON & JOHNSON14.16%320 836
ROCHE HOLDING LTD.-11.51%216 029
NOVARTIS AG-10.14%209 049
PFIZER INC.3.22%202 108
MERCK & CO., INC.17.21%171 194
More Results